Business
DiaMedica Therapeutics Provides a Business Update and Announces Full Year 2024 Financial Results
MINNEAPOLIS, March 17, 2025--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for acute ischemic stroke and preeclampsia, today provided a business update and financial results for the year ended December 31, 2024. Management will host a conference call Tuesday, March 18, 2025, at 8:00 AM Eastern Time / 7:00 AM Central Time to discuss its business update and full year 2024 financial results.
About this update from Diamedica Therapeutics Inc.
[{"type":"image","alt":"","displaySize":"","headline":null,"caption":"","credit":null,"className":"","disableSlideshowImg":false,"size":{"original":{"width":2000,"height":631,"url":"https://media.zenfs.com/en/business-wire.com/0d031128289142a1faa95721ee0875ec"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/60ALVBaJGEFrT4vBHyfalA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTk2MDtoPTMwMztjZj13ZWJw/https://media.zenfs.com/en/business-wire.com/0d031128289142a1faa95721ee0875ec","width":960,"height":303},"lightbox":{"url":"https://s.yimg.com/ny/api/res/1.2/O8NK37g.SMntphVNQ1PC8Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTI0MDA7aD03NTg7Y2Y9d2VicA--/https://media.zenfs.com/en/business-wire.com/0d031128289142a1faa95721ee0875ec","width":1200,"height":379}},"lazy":false},{"type":"text","content":"Conference Call and Webcast March 18 at 8:00 AM Eastern Time / 7:00 AM Central Time","length":83,"tagName":"p","attribs":{}},{"type":"list","items":[{"val":[{"type":"text","content":"Preeclampsia Phase 2 Trial Preliminary Topline Safety and Efficacy Data from Part 1A of the Study Expected in the Second Quarter of 2025","length":136,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Acute Ischemic Stroke Phase 2/3 Program Enrollment Ongoing","length":58,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Appointed Experienced Biotech Executive Daniel J. O’Connor to the Board","length":71,"tagName":"p","attribs":{}}]},{"val":[{"type":"text","content":"Cash Runway into Q3 2026","length":24,"tagName":"p","attribs":{}}]}],"tagName":"ul","bulletedList":true,"length":289,"olType":false},{"type":"text","content":"MINNEAPOLIS, March 17, 2025--(BUSINESS WIRE)--DiaMedica Therapeutics Inc. (Nasdaq: DMAC), a clinical-stage biopharmaceutical company focused on developing novel treatments for acute ischemic stroke and preeclampsia, today provided a business update and financial results for the year ended December 31, 2024. Management will host a conference call Tuesday, March 18, 2025, at 8:00 AM Eastern Time / 7:00 AM Central Time to discuss its business update and full year 2024 financial results.","length":488,"tagName":"p"},{"type":"text","content":""We made significant progress in 2024, advancing our AIS program and expanding into preeclampsia," said Rick Pauls, President and CEO of DiaMedica. "Both of these populations are critically underserved, representing substanti...